Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments. Specific types of chemotherapy and chest-directed radiation therapy are known to cause cardiac dysfunction, mainly due to cardiotoxicity — the symptoms of which may not present until months or even years after cancer treatment. 


Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI)-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure.

Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance.

May 10, 2016 — Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT) at five years follow-up. The findings are published in Annals of Internal Medicine.

Medtronic plc announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions, May 4-7 in San Francisco.

The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in cardiac resynchronization therapy (CRT) patients.

Amputation Prevention Symposium (AMP)

Results from a first-of-its-kind study identify a significant increase in the incidence of atrial fibrillation (AF) among patients with pacemaker-detected sleep apnea.

A new study shows the use of novel anticoagulants to treat atrial fibrillation (AF) on an “as needed basis” guided by diligent pulse monitoring can be an effective and safe way to lower overall risk of stroke.

May 9, 2016 — New data presented at the Heart Rhythm Society's (HRS) annual meeting highlighted the long-term safety of the retrievability of the St. Jude Medical Nanostim leadless pacemaker. Two additional presentations also showed that the Nanostim leadless pacemaker is associated with reduced rates of acute and mid-term complications compared to traditional pacemakers with leads and can improve quality of life for patients.

Subscribe Now